Intervention Review

You have free access to this content

Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults

  1. Mattias Linde1,*,
  2. Wim M Mulleners2,
  3. Edward P Chronicle3,
  4. Douglas C McCrory4,5

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 24 JUN 2013

Assessed as up-to-date: 15 JAN 2013

DOI: 10.1002/14651858.CD010608


How to Cite

Linde M, Mulleners WM, Chronicle EP, McCrory DC. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010608. DOI: 10.1002/14651858.CD010608.

Author Information

  1. 1

    Norwegian University of Science and Technology, Department of Neuroscience, Trondheim, Norway

  2. 2

    Canisius Wilhelmina Ziekenhuis, Department of Neurology, Nijmegen, Netherlands

  3. 3

    University of Hawaii at Manoa, (Deceased) Department of Psychology, Manoa, USA

  4. 4

    Duke University Medical Center, Department of Medicine, Durham, NC, USA

  5. 5

    Durham Veterans Affairs Medical Center, Center for Health Services Research in Primary Care, Durham, NC, USA

*Mattias Linde, Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway. mattias.linde@ntnu.no.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JUN 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Acetazolamide versus placebo, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Carbamazepine versus placebo, Outcome 1 OR for responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Carbamazepine versus placebo, Outcome 2 RR for responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Carbamazepine versus placebo, Outcome 3 Any adverse event.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Carbamazepine versus placebo, Outcome 4 Drowsiness.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Carbamazepine versus placebo, Outcome 5 Nausea.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Carbamazepine versus placebo, Outcome 6 Vertigo/giddiness.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Carisbamate versus placebo, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 4.1]
Analysis 4.1. Comparison 4 Carisbamate dose comparisons, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 5.1]
Analysis 5.1. Comparison 5 Clonazepam versus placebo, Outcome 1 Headache frequency (post-treatment; headache days per month).
[Analysis 6.1]
Analysis 6.1. Comparison 6 Lamotrigine versus placebo, Outcome 1 Headache frequency (change from baseline to post-treatment, or post-treatment alone).
[Analysis 6.2]
Analysis 6.2. Comparison 6 Lamotrigine versus placebo, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 7.1]
Analysis 7.1. Comparison 7 Lamotrigine versus topiramate, Outcome 1 Headache frequency (change from baseline to post-treatment).
[Analysis 7.2]
Analysis 7.2. Comparison 7 Lamotrigine versus topiramate, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Levetiracetam versus placebo, Outcome 1 Headache frequency (post-treatment; headache days per month).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Levetiracetam versus placebo, Outcome 2 OR for responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 8.3]
Analysis 8.3. Comparison 8 Levetiracetam versus placebo, Outcome 3 RR for responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 9.1]
Analysis 9.1. Comparison 9 Levetiracetam versus topiramate, Outcome 1 Headache frequency (post-treatment; headache days per month).
[Analysis 9.2]
Analysis 9.2. Comparison 9 Levetiracetam versus topiramate, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 10.1]
Analysis 10.1. Comparison 10 Oxcarbazepine versus placebo, Outcome 1 Headache frequency (change from baseline to post-treatment).
[Analysis 10.2]
Analysis 10.2. Comparison 10 Oxcarbazepine versus placebo, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 11.1]
Analysis 11.1. Comparison 11 Vigabatrin versus placebo, Outcome 1 Headache frequency (post-treatment).
[Analysis 12.1]
Analysis 12.1. Comparison 12 Zonisamide versus topiramate, Outcome 1 Headache frequency (change from baseline to post-treatment).